PFS Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

PFS Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-120	Closed	-$3.07K	–	446
2024 Q3	$3.07K	Buy	+120	New	+$3.06K	﹤0.01%	380

Other funds holding ARKG

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PFS Partners's ARKG Position: Q4 2024 in Review

PFS Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2024, closing a stake of 120 shares — an estimated $3.07K sold.

PFS Partners first reported a position in ARKG in Q3 2024 and held it in 1 quarter. The position peaked at $3.07K in Q3 2024. 238 funds tracked by Wall St. Rank hold ARKG as of Q4 2024.

PFS Partners reported no remaining ARK Genomic Revolution ETF position as of Q4 2024 after selling out during the quarter.
PFS Partners sold 120 ARK Genomic Revolution ETF shares in Q4 2024, an estimated $3.07K.
PFS Partners first reported a position in ARK Genomic Revolution ETF in Q3 2024 and held it in 1 quarter.
PFS Partners's ARK Genomic Revolution ETF position peaked at $3.07K in Q3 2024.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2024.

Based on PFS Partners's 13F filing for Q4 2024, filed 27 Jan 2025.